Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing implications of mouse clinical trials (MCTs) for more predictive outcomes, and ongoing innovations in mice models are driving the growth of the global mice model industry.
The global mice model market size is projected to reach USD 1.9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4% during the forecast period.
Growing Usage Of Mice Models In Virology And Infectious Diseases
Over the years, there has been an increase in the incidence of viral infectious diseases. In the past two decades, coronavirus outbreaks have taken place three times—SARS-CoV in 2002, MERS-CoV in 2012, and SARS-CoV-2 in 2019. However, the current SARS-CoV-2 is much more severe than the SARS-CoV in 2002 and has spread to more than 213 countries affecting millions of individuals. The emergence of the novel coronavirus disease in 2019 (COVID-19) has prompted the use of animal models for the study of its pathology and the development of effective treatment.
Apart from coronavirus studies, mice models are considered to be the best small animal models for hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV), among others. According to the WHO, infectious diseases kill more than 17 million people every year. In the last two decades, over 30 new infectious diseases have emerged. According to UNAIDS, by the end of 2019, 38 million individuals were affected by HIV. Mice models have been used widely for several different viral investigations due to their small size, low cost, easy operation, and high reproducibility.
Download PDF Brochure:
Opportunity: Rising Demand For Humanized Mice Models
Humanized mice models are important tools for conducting preclinical research to gain insights into human biology. These models are developed through the engraftment of human cells or tissues, leading to the expression of human proteins in mice.
Humanized mice are increasingly being used as models for biomedical research applications, such as cancer, infectious diseases, HIV/AIDS, regenerative medicine, and hepatitis. In March 2019, the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the US Department of Health and Human Services, announced funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The need to identify the actual effects of drugs on humans, as well as the growing focus on studying human-specific infections, therapies, and immune responses, is promoting the development and use of humanized mice models.
Technology used to create transgenic mice, the mice model market is categorized into the CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies (includes virus/vector-mediated gene transfer, and TALENs & ZFNs) segments. CRISPR is the most widely used technology in the mice model market and contributed to the largest share of the mice model market in 2020. Ease of design, high efficiency, and relatively lower cost have increased the demand for CRISPR-customized mice models.
Request for Sample Pages:
Geographical Region Covered in Mice Model Industry
Global mice model market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2019, North America accounted for the largest share of the mice model market. The large share of the North America region can be attributed to the presence of major players operating in the mice model market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Key Players in Mice Model Industry
Charles River Laboratories, (US) The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Envigo (US), JANVIER LABS (France), genOway (France), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioservices (France), Ingenious Targeting Laboratory (US), Cyagen Biosciences (US), GVK BIO (India), The Andersons, Inc. (US), Innovive (US), Allentown, LLC (US), FENGSHI Group (China), Ozgene Pty Ltd. (Australia), and Harbour Biomed (US)